Dusan Sajic, PhD, MD, FRCPC, FAAD

Guelph Dermatology Research

33 Farley Drive, Unit 8
Guelph, Ontario, Canada
N1L 0B7
519-836-8558 ext. 5


Specialty: Dermatology


Research Interests: Acne, Actinic Keratoses, Atopic Dermatitis, Basal Cell Carcinoma, Dermatitis, Psoriasis, Rosacea, Squamous Cell Carcinoma

Dr. Sajic completed an Honours BSc in Biology at McMaster University followed by a PhD in Molecular Immunology Virology and Inflammation at McMaster University. There he looked at molecular pathways involved in the activation of the immune system. He was awarded the Ontario Graduate Scholarship for each of the years he attended. He did his medical training at the University of Western Ontario Followed by a Residency in Dermatology at the University of Toronto. During his studies he was one of the few Males to be awarded the Women’s Dermatologic Society Mentorship Award – an award designed to develop leadership potential in candidates who have shown early promise through exceptional activities, which will enhance their contributions to dermatology and medicine.  This was completed at the University of Minnesota’s Mayo Building where he studied the role of Stem Cell Transplantation therapy in the role of wound healing in Epidermolysis Bullosa – a genetic disorder with severely fragile skin that leads chronic non healing wounds throughout the entire body. Furthermore, he was awarded with a prestigious Principal Investigator Research Grant from the Canadian Dermatology Foundation during his final year of Dermatology Residency Training.


Since that time Dr Sajic has been a full time active Dermatologist at both the Guelph Dermatology and is an Associate Investigator at Probity Medical Research where he is currently conducting several phase 2 and 3 clinical studies.  He is a Fellow of the Royal College of Physicians and Surgeons of Canada as well the American Academy of Dermatology. Dr. Sajic has extensive training in medical, surgical and aesthetic dermatology. He sits on a number of advisory boards and is an active member of the Canadian Dermatology Association, Dermatology Association of Ontario, American Academy of Dermatology, American Society for Dermatologic Surgery, Ontario Medical Association and Canadian Medical Association.


Click to view Dr. Dusan Sajic's Publications

Boull CL, Hylwa SA, Sajic D, Wagner JE, Tolar J, Hook KP.  Toxic Epidermal Necrolysis in Recessive Dystrophic Epidermolysis Bullosa following Bone Marrow Transplantation.  J Pediatr 2016 Jun; 173: 242-4.  PMID: 26976809 / doi: 10.1016/j.jpeds.2016.02.037

Qiang JK, Marinas JE, Sajic D, Yeung J.  Serpiginous mycosis fungoides in a 21-year-old man.  JAAD Case Rep 2015 Mar; 1(2): 82-4.  PMID: 27051691 / doi: 10.1016/j.jdcr.2015.01.009

Alavi A, Sajic D, Cerci FB, Ghazarian D, Rosenbach M, Jorizzo J.  Neutrophilic dermatoses: an update.  Am J Clin Dermatol 2014 Oct; 15(5): 413-23.  PMID: 25154386 / doi: 10.1007/s40257-014-0092-6

Sajic D, Archibald J, Murray C.  Surface anatomy of the ear.  J Cutan Med Surg 2014 Mar-Apr; 18(2): 137-40.  PMID: 24636441 / doi: 10.2310/7750.2013.13057

McCluskie MJ, Cartier JL, Patrick AJ, Sajic D, Weeratna RD, Rosenthal KL, Davis H.  Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).  Antiviral Res 2006 Feb; 69(2): 77-85.  Epub 2015 Dec 5.  PMID: 16377001 / doi: 10.1016/j.antiviral.2005.10.007

Sajic D, Skotnicki-Grant S.  Ceramide-based Moisturizers as Treatment for Pediatric Atopic Dermatitis.  Skin Therapy Letter Family Practice Edition 2013 May; 9(1): 1-3.

Sajic D, Skotnicki-Grant S.  Advances in Topical Acne Therapy: New Molecules, Vehicles and Delivery Mechanisms.  Skin Therapy Letter Family Practice Edition 2012 Dec; 8(2): 1-3.

Sajic D, Asiniwasis R, Skotnicki-Grant S.  Look at Epidermal Barrier Function in Atopic Dermatitis: Physiologic Lipid Replacement and the Role of Ceramides.  Skin Therapy Letter 2012 Jul-Aug; 17(7): 6-9.

Asiniwasis R, Sajic D, Skotnicki-Grant S.  Atopic Dermatitis: The Skin Barrier and the Role of Ceramides.  Skin Therapy Letter Family Practice Edition 2011 Oct; 7(5): 5-8.

Sajic D, Patrick AJ, Rosenthal KL.  Mucosal delivery of CpG oligodeoxynucleotides expands functional dendritic cells and macrophages in the vagina.  Immunology 2005 Feb; 114(2): 213-24.  PMID: 15667566 / doi: 10.1111/j.1365-2567.2004.02081.x

Ashkar AA, Yao XD, Gill N, Sajic D, Patrick AJ, Rosenthal KL.  Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA.  J Infect Dis 2004 Nov; 190(10): 1841-9.  PMID: 15499542 / doi: 10.1086/425079

Sajic D, Ashkar AA, Patrick AJ, McCluskie MJ, Davis HL, Levine KL, Holl R, Rosenthal KL.  Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.  J Med Virol 2003 Dec; 71(4): 561-8.  PMID: 14556270 / doi: 10.1002/jmv.10518

Swirski FK, Sajic D, Robbins CS, Gajewska BU, Jordana M, Stämpfli MR.  Chronic exposure to innocuous antigen in sensitized mice leads to suppressed airway eosinophilia that is reversed by granulocyte macrophage colony-stimulating factor.  J Immunol 2002 Oct; 169(7): 3349-506.  PMID: 12244139


Copyright 2014 Probity Medical Research Inc. All Rights Reserved.